Lotus Eye Hospital And Institute Ltd

Lotus Eye Hospital And Institute Ltd - Closure of Trading Window

AGM Details

• Date and time: 23 September 2026, 4:00 PM to 4:25 PM, via VC/OAVM.
• Record date: 16 September 2026.
• Shareholders on record: 9,842.
• Four resolutions were put to vote and passed.

Key Resolutions

• Ordinary resolution: Adoption of audited financial statements for year ended 31 March 2024.
• Ordinary resolution: Re-appointment of director by rotation.
• Special resolution: Approval of remuneration revision for Managing Director.
• Special resolution: Continuation of remuneration for Non-Executive Non-Independent Director.

Voting Results

• Resolution 1: 99.39% in favour; 0.61% against.
• Resolution 2: 81.27% in favour; 18.73% against.
• Resolution 3: 76.43% in favour; 23.57% against.
• Resolution 4: 94.54% in favour; 5.46% against.

Director Changes

• Director re-appointment by rotation approved.

AGM Details

• AGM held on September 23, 2026 at 04:00 PM IST via VC/OAVM.

Financial Highlights Presented

• CFO briefed shareholders on financial highlights for FY2025-26.

Audit Report

• Unmodified audit report for FY2025-26 presented to shareholders.

MD Address & Attendance

• MD briefed on services for the financial year 2025-26.
• Requisite quorum was present at the meeting.

Financial performance

• Revenue from operations: 5,371.41 lakhs in FY2025-26.
• Total income: 5,489.03 lakhs; expenses 5,493.98.
• Profit before tax: -5.36 lakhs; tax expense 13.40; PAT 8.04.
• Total comprehensive income: 3.73; earnings per share: 0.04.
• Net debt: 1,210.76 lakhs; debt-to-equity ratio 20.13%.

Capital structure & liquidity

• Authorized share capital: 2,500.00 lakhs; issued/subscribed: 2,079.63.
• Total borrowings: 1,583.37 lakhs; long-term 1,300.96; short-term 282.41.
• Cash & bank balances: 180.83; other balances: 201.83; total cash 372.61.
• Net worth: 6,013.76 lakhs.

Operations & expansion

• Ten eye care centers in Tamil Nadu and Kerala (eight TN, two Kerala).
• Gobichettipalayam centre commenced operations; expansion drives costs.
• ZEISS VISUFIT 1000 3D facial scanning launched at SITRA.
• Launched Lotus Optique at SITRA; milestones achieved in 2026.

Remuneration & governance

• MD remuneration proposed to increase to Rs 6.00 lakh per month from Aug 10, 2026.
• Remuneration for Dr. Ramalingam continued at Rs 1.00 lakh/month for 2026-27.
• Board: six directors; two women; five meetings in FY2025-26.
• Fines for Reg 17(1A) non-compliance paid; postal ballot approved 17-01-2026.
• Company Secretary appointed: Prathish S on Feb 13, 2026.

Governance & risk

• Statutory Auditor: Anbarasu & Jalapathi; no qualifications.
• Secretarial audit flagged intimation gaps; company addressed via compliance.
• Board compliant with SEBI LODR; familiarization programme conducted.

CSR & sustainability

• CSR expenditure: 6.07 lakhs; unspent CSR balance 1,20,900.
• Unspent CSR carried from 2024-25: 7,27,900; 2025-26 spent: 6,07,000.
• One CSR asset: vehicle for medical camps funded at 6.07 lakhs.
• CSR policy disclosed on company site.

Shareholding & dividends

• Dividend for FY2025-26: not declared.
• Promoter holdings: Sangeetha Sundaramoorthy 34.98%; Kavetha Sundaramoorthy 2.75%; others.
• Total promoter stake: 40.14%; total issued capital: 2,079.63 lakh.

AGM Details

• Date/time/mode: meeting to be held via VC/OAVM as stated in notice.
• Remote e-voting window and cut-off details provided in notice.
• Record/book closure dates not mentioned.

Key Resolutions

• Ordinary: Adoption of audited financial statements for the latest year.
• Ordinary: Re-appointment of director by rotation.
• Ordinary: MD remuneration revision approved to a higher monthly amount.
• Special: Continuation of remuneration for Non-Executive Director for the next year.

Director Changes

• Retiring director to be considered for re-appointment.

Related Parties

• MD and another director are sisters.

Overview

• Lotus Eye Hospital launches Lotus Optique at SITRA campus in Coimbatore.
• Store features ZEISS VISUFIT 1000 3D facial scanning for frame selection and fitting.

Financial results and governance

• Standalone unaudited results for quarter ended June 30, 2026 approved; Limited Review Report issued.
• Board notes no subsidiaries/associates; consolidation not applicable.
• Single segment: Eye Care related sales and services.
• Audit committee reviewed; board approved the results on 10 August 2026.
• Statutory auditors conducted a limited review; no audit opinion issued.
• Notes: Exceptional item relates to profit/loss on sale of PPE.

Dematerialisation status

• Dematerialisation requests processed and confirmed to depositories; listed on stock exchanges.
• Certificates received for dematerialisation mutilated and cancelled after verification.
• Depository's name substituted as registered owner within prescribed timelines.